Actively Recruiting
Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy
Led by Kasr El Aini Hospital · Updated on 2026-05-01
25
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying androgenetic alopecia, a common form of progressive hair loss affecting adult males aged 18 to 50 years. This prospective single-arm interventional study aims to compare tissue levels of Janus Kinase 2 (JAK2) protein in balding versus non-balding scalp areas at the start and to evaluate changes in JAK2 expression in the balding scalp after 3 months of treatment with topical minoxidil 5%. The study also assesses clinical response through standardized trichoscopic hair evaluations. Participants will receive topical minoxidil 5% solution applied to the scalp for 12 weeks, with men applying 1 cc twice daily. At the beginning, clinical exams, photography, and trichoscopic assessments will be conducted. Three 2 mm scalp punch biopsies will be collected: one from the balding area and one from the non-balding area at baseline, and another from the balding area after treatment. JAK2 protein levels will be measured by ELISA from these tissue samples. During the study, participants will undergo multiple clinical and trichoscopic evaluations and biopsies to monitor changes in hair parameters and JAK2 levels. Researchers will observe differences in JAK2 protein between balding and non-balding scalp at baseline and changes after minoxidil treatment. The study includes safety monitoring and will last for at least 12 weeks of treatment with follow-up assessments.
CONDITIONS
Brief Title
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male adults aged 18 to 50 years with androgenetic alopecia
- Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V
- Treatment-naive patients or those willing to undergo at least 1 month washout from prior hair loss therapies
- Willing and able to provide written informed consent
You will not qualify if you...
- Other types of hair loss such as inflammatory or scarring alopecia
- Presence of inflammatory scalp skin conditions like psoriasis or seborrheic dermatitis
- Use of systemic immunosuppressants, JAK inhibitors, or corticosteroids in the past 12 months
- History of severe systemic diseases including kidney, heart, or liver disease
- Chemotherapy within the last 5 years
- Bleeding disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men apply 1 cc twice daily and women apply 1 cc once daily. Clinical evaluation, standardized photography, and trichoscopic assessment are performed at baseline. Three 2 mm scalp punch biopsies are obtained: two at baseline from balding and non-balding scalp areas and one from the balding scalp after 12 weeks of treatment for tissue JAK2 protein measurement.
2 visits: 1 baseline visit and 1 visit after 12 weeks
Trial Site Locations
Total: 1 location
1
Kasr El Aini Hospital
Cairo, Cairo Governorate, Egypt, 11555
Actively Recruiting
Research Team
H
Heba Ahmed
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here